CN-118666965-B - Polypeptide and polypeptide solution for resisting skin and wound infection pathogenic bacteria and application

Abstract

The invention belongs to the field of medical application, and in particular relates to a polypeptide and a polypeptide solution for resisting skin and wound infection pathogenic bacteria and application thereof. The polypeptide for resisting skin and wound infection pathogenic bacteria can effectively inhibit or kill staphylococcus aureus, pseudomonas aeruginosa and escherichia coli, and the amino acid sequence of the polypeptide for resisting skin and wound infection pathogenic bacteria is Phe-Leu-Lys-Lys-Ala-Ala-Lys-Lys-Leu-Leu-Lys-Lys-Leu-Phe. Meanwhile, the polypeptide has good stability and very low toxicity. The polypeptide has the potential of being developed into antibacterial gel, spray preparation and medicine coating with the effects of resisting staphylococcus aureus, pseudomonas aeruginosa and escherichia coli, and is used for preventing and treating infectious diseases such as skin and wound infection and the like caused by staphylococcus aureus, pseudomonas aeruginosa and escherichia coli.

Inventors

• LIANG GAOFENG
• LI ZHONGJIE
• DENG BO
• LI SHASHA

Assignees

• 河南科技大学

Dates

Publication Date

20260508

Application Date

20240530

Claims (9)

1. 1. A polypeptide for resisting pathogenic bacteria of skin and wound infection is characterized in that the amino acid sequence of the polypeptide for resisting pathogenic bacteria of skin and wound infection is shown as SEQ ID NO.1, namely Phe-Leu-Lys-Lys-Ala-Ala-Lys-Lys-Leu-Leu-Lys-Lys-Leu-Phe; the pathogenic bacteria include staphylococcus aureus, pseudomonas aeruginosa and escherichia coli.
2. 2. A polypeptide solution comprising the polypeptide against pathogenic bacteria of skin and wound infection of claim 1, wherein the polypeptide solution is obtained by dissolving the polypeptide against pathogenic bacteria of skin and wound infection in a solvent.
3. 3. The polypeptide solution of claim 2, wherein the solvent is physiological saline.
4. 4. Use of a polypeptide of claim 1 or a polypeptide solution of any one of claims 2-3 for the preparation of a bacteriostatic agent for inhibiting staphylococcus aureus, pseudomonas aeruginosa and escherichia coli.
5. 5. Use of the polypeptide of claim 1 or the polypeptide solution of any one of claims 2-3 for the preparation of a bactericide, wherein the bactericide is used for killing staphylococcus aureus, pseudomonas aeruginosa and escherichia coli; the minimum concentration of the polypeptide solution for killing staphylococcus aureus is 25 mug/mL, and the minimum concentration of the polypeptide solution for killing pseudomonas aeruginosa and escherichia coli is 50 mug/mL.
6. 6. Use of a polypeptide of claim 1 against pathogenic bacteria of skin or wound infection or of a polypeptide solution of any one of claims 2-3 for the preparation of a medicament for the treatment of skin or wound infection, wherein the pathogenic bacteria responsible for the skin or wound infection are any one or a combination of several of staphylococcus aureus, pseudomonas aeruginosa and escherichia coli.
7. 7. The use according to claim 6, wherein the medicament comprises the polypeptide having the sequence shown in SEQ ID NO.1 as the only active ingredient.
8. 8. The use according to claim 7, wherein the medicament further comprises other pharmaceutically acceptable excipients.
9. 9. The use according to claim 8, wherein the adjuvant comprises any one or more of sodium alginate, chitosan, polyvinyl alcohol, bran amine, aldehyde dextran, adipic acid dihydrazide, tween 60, lauramidopropyl betaine, jasminoidin, gardenia oil, and the like.

Description

Polypeptide and polypeptide solution for resisting skin and wound infection pathogenic bacteria and application Technical Field The invention relates to the field of medical application, in particular to a polypeptide and polypeptide solution for resisting skin and wound infection pathogenic bacteria and application thereof. Background Bacterial infectious diseases are a common type of disease, especially skin and wound infections. Staphylococcus aureus, pseudomonas aeruginosa and escherichia coli are common main pathogenic bacteria causing skin and wound infection, and although traditional antibiotics can be used for effective treatment, the problem of drug resistance is easily caused. The drug resistance of staphylococcus aureus, pseudomonas aeruginosa and escherichia coli is very severe at present, so that the treatment effect is seriously affected, and a series of social problems are brought. The antibacterial polypeptide is a polypeptide active molecule, can effectively kill different types of pathogenic bacteria, and can also kill related drug-resistant strains. Meanwhile, the antibacterial polypeptide is not easy to induce bacteria to generate drug resistance due to multiple and different action mechanisms of the antibacterial polypeptide from the traditional antibiotics. Therefore, the antibacterial polypeptide has great attraction and development and application prospects, and is a hotspot for developing novel antibacterial drugs in the field of medicines. Therefore, the antibacterial polypeptide has great attraction and application prospect in the research and development and utilization of novel antibacterial drugs in the field of medicine. The existing polypeptide capable of simultaneously resisting multiple pathogenic bacteria infection is relatively single. Thus, there is a need to obtain an antimicrobial polypeptide that is resistant to pathogenic bacteria from skin and wound infections. Disclosure of Invention The invention provides a pathogenic bacteria polypeptide for resisting skin and wound infection, a polypeptide solution and application, and the pathogenic bacteria polypeptide for resisting skin and wound infection can effectively inhibit or kill pathogenic bacteria causing skin or wound infection: staphylococcus aureus, pseudomonas aeruginosa and escherichia coli, and meanwhile, the polypeptide has good stability and low toxicity. The invention provides a pathogenic bacteria polypeptide for resisting skin and wound infection, the amino acid sequence of which is shown as SEQ ID NO.1, phe-Leu-Lys-Lys-Ala-Ala-Lys-Lys-Leu-Leu-Lys-Lys-Leu-Phe; the pathogenic bacteria include staphylococcus aureus, pseudomonas aeruginosa and escherichia coli. The invention provides a novel antibacterial polypeptide, which enriches the sources of antibacterial polypeptide products. Also lays a product foundation for clinically preparing medicines for skin and wound infection. The invention also provides a polypeptide solution containing the polypeptide against skin and wound infection pathogenic bacteria, wherein the polypeptide solution is prepared by dissolving the polypeptide against skin and wound infection pathogenic bacteria by a solvent. Further, the physiological saline may be replaced with ultrapure water, phosphate buffer, or acetic acid. Further, the concentration of the polypeptide solution is 6.25-100. Mu.g/mL. The invention also provides application of the polypeptide or the polypeptide solution for resisting skin and wound infection pathogenic bacteria in preparation of a bacteriostatic agent, wherein the bacteriostatic agent is used for inhibiting staphylococcus aureus, pseudomonas aeruginosa and escherichia coli. Further, the minimum inhibitory concentration of the polypeptide solution to staphylococcus aureus is 6.25 mug/mL, the minimum inhibitory concentration to pseudomonas aeruginosa is 12.5 mug/mL, and the minimum inhibitory concentration to escherichia coli is 12.5 mug/mL. The invention also provides application of the polypeptide or the polypeptide solution for resisting skin and wound infection pathogenic bacteria in preparing bactericides, wherein the bactericides are used for killing staphylococcus aureus, pseudomonas aeruginosa and escherichia coli; the minimum concentration of the polypeptide solution for killing staphylococcus aureus is 25 mug/mL, and the minimum concentration of the polypeptide solution for killing pseudomonas aeruginosa and escherichia coli is 50 mug/mL. The invention also provides application of the polypeptide for resisting skin and wound infection pathogenic bacteria or the polypeptide solution in preparing medicines for treating skin or wound infection pathogenic bacteria which cause skin or wound infection are any one or a combination of a plurality of staphylococcus aureus, pseudomonas aeruginosa and escherichia coli. Further, the medicine takes the polypeptide with the sequence shown as SEQ ID NO.1 as the only effective component. Further, the medicame